hotspot -WSS

hotspot

author：explore 2025-10-01 11:34:02 - browse：9123

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Anthony Fauci pushes back on GOP claims during Covid hearing

WSS

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Hospitals are piloting generative AI tools as regulators play catch

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Senators tussle over abortion against the backdrop of a presidential campaign

For pregnant people, addiction treatment shouldn't mean a call to child protective services

FTC loses bid to block Novant's North Carolina hospital merger

focus

hotspot

Sign up for D.C. Diagnosis

focus

Heart attack and stroke risk calculators need revising

CMS got Medicare Advantage quality rating wrong, judge rules

In Memoriam: Notable people who died in 2023

Congress needs to close a vaccine

Virginia high school admissions case could be legal follow

Researchers tackle phage therapy hurdles for wider adoption

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CMS got Medicare Advantage quality rating wrong, judge rules

Medicare proposal to cover medical devices draws a mixed reaction

Fight over Supreme Court dialysis ruling puts kidney patients at risk

entertainment

In 'major milestone,' FDA approves first cell therapy for solid tumors

The most pressing bird flu mysteries scientists want answered

Sutter Health’s antitrust win overturned by appeals court

An outdated Medicare rule harms dementia patients with anxiety

Opioid cravings were reduced by anti

Reporting on presidential health from Reagan to Trump and Biden

leisure time

leisure time

hotspot

Wikipedia